Imugene

The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication for persons with neurological disorders and eventually revolutionizing human-AI interaction for everyone.

Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedic spine conditions, and cardiovascular disorders.

Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services using technology for measuring the human gut microbiota. The company analyzes the microbiome to discover therapeutics, develop new diagnostic tools to understand disease through comprehensive measurement of the human gut microbiome. Microba Life Sciences was established in March 2017 by Philip Hugenholtz and Gene Tyson in Brisbane, Queensland.

Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is economically viable.

Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver pharmaceutical therapies to improve patients’ health and quality of life

BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.

Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial levels more quickly and affordably than conventional methods.

HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste biomass — without electrolysis. By focusing first on green ammonia and fertilizer production, our cost-competitive, carbon-negative hydrogen offers a scalable alternative to fossil-based feedstocks. HydGene’s technology eliminates hydrogen transport and storage costs by generating it where it’s needed, unlocking faster and more affordable decarbonisation across the chemical industry. Founded in 2021 in Sydney, Australia, and backed by leading investors and strategic partners, HydGene is pioneering the next generation of clean hydrogen solutions to accelerate the global shift to net zero. Founding team: Dr Louise Brown, Prof Robert Willows, Dr Natalie Curach, Dr Kerstin Petroll.

Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more accessible genomics data.

OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue. OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leading researchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system. With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure.

Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.